BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pilbara Health Professional Network - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pilbara Health Professional Network
X-ORIGINAL-URL:https://www.phpn.com.au
X-WR-CALDESC:Events for Pilbara Health Professional Network
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Australia/Perth
BEGIN:STANDARD
TZOFFSETFROM:+0800
TZOFFSETTO:+0800
TZNAME:AWST
DTSTART:20190101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Australia/Perth:20200526T170000
DTEND;TZID=Australia/Perth:20200526T180000
DTSTAMP:20260502T123938
CREATED:20200519T013459Z
LAST-MODIFIED:20200519T013459Z
UID:10002598-1590512400-1590516000@www.phpn.com.au
SUMMARY:Managing moderate and severe asthma: Ignite Webinar
DESCRIPTION:Tuesday 26th May 2020\n7:00pm – 8:00pm (AEST) \nProfessor Norbert Berend\, Global Medical Expert\, GSK \nThis webinar will discuss treatment options including recent developments for patients with moderate and severe asthma. The role of anti-IL5 monoclonal antibodies for the treatment of severe eosinophilic asthma will also be reviewed. \nLearning Objectives: \n\nUnderstand differences in the real world effectiveness of ICS/LABA medications\nDiscuss the burden of severe asthma including the impact of exacerbations and OCS use\nDiscuss the role of primary care physicians in supporting the identification and post treatment management of severe asthma patients\n\nIntroduction to Nucala(mepolizumab) including\, efficacy\, long term safety and the introduction of a new formulation for self-administration\n\nFind out more and register here.
URL:https://www.phpn.com.au/event/managing-moderate-and-severe-asthma-ignite-webinar/
LOCATION:WA\, Australia
CATEGORIES:Health
END:VEVENT
END:VCALENDAR